Blood Coagulants Market Research Report - Global Forecast till 2027

Blood Coagulants Market Research Report: Information by Type (Coagulation Factor (Recombinant Coagulation Factor & Plasma-Derived Coagulation Factor) & Others), & Indication (Hemophilia, Surgery, & Other Bleeding Disorders)—Forecast till 2027

ID: MRFR/HC/6163-HCR | August 2022 | Region: Global | 160 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Blood Coagulants Market, by Type

6.1 Overview

6.2 Coagulation Factor

6.2.1 Recombinant Coagulation Factor

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 Plasma-Derived Coagulation Factor

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Blood Coagulants Market, by Indication

7.1 Overview

7.2 Hemophilia

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Other Bleeding Disorders

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Blood Coagulants Market, by Region

8.1 Overview

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 Latin America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9. Company Landscape

9.1 Overview

9.2 Market Share Analysis

Chapter 10. Company Profiles

10.1 Aptevo Biotherapeutics LLC

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Baxalta US Inc.

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Baxter Laboratories

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Bayer AG

10.4.1 Company Overview

10.4.2 Product Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 CSL Behring

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 GRIFOLS USA, LLC

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Novo Nordisk A/S

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Octapharma

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 Pfizer

10.9.1 Overview

10.9.2 Product Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Shire

10.10.1 Overview

10.10.2 Product Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.11 SOBI

10.11.1 Overview

10.11.2 Product Overview

10.11.3 Financials

10.11.4 Key Developments

10.11.5 SWOT Analysis

10.12 Others

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.3 Predictions for the Blood Coagulants Industry

Chapter 12. Appendix 

LIST OF TABLES

Table 1 Global Blood Coagulants Market Synopsis, 2020–2027

Table 2 Global Blood Coagulants Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 4 Global Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 5 Global Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 6 North America: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 7 North America: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 8 North America: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 9 US: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 10 US: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 11 US: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 12 Canada: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 13 Canada: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 14 Canada: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 15 South America: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 16 South America: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 17 South America: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 18 Europe: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 19 Europe: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 20 Europe: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 21 Western Europe: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 22 Western Europe: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 23 Western Europe: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 24 Eastern Europe: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 25 Eastern Europe: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 26 Eastern Europe: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 27 Asia-Pacific: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 28 Asia-Pacific: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 29 Asia-Pacific: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

Table 30 Middle East & Africa: Blood Coagulants Market, by Type, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Blood Coagulants Market, by Indication, 2020–2027 (USD Million)

Table 32 Middle East & Africa: Blood Coagulants Market, by Region, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Blood Coagulants Market

Figure 3 Segmentation Market Dynamics for Global Blood Coagulants Market

Figure 4 Global Blood Coagulants Market Share, by Type, 2020 (%)

Figure 5 Global Blood Coagulants Market Share, by Indication, 2020 (%)

Figure 6 Global Blood Coagulants Market Share, by Region, 2020 (%)

Figure 7 North America: Blood Coagulants Market Share, by Country, 2020 (%)

Figure 8 Europe: Blood Coagulants Market Share, by Country, 2020 (%)

Figure 9 Asia-Pacific: Blood Coagulants Market Share, by Country, 2020 (%)

Figure 10 Middle East & Africa: Blood Coagulants Market Share, by Country, 2020 (%)

Figure 11 Global Blood Coagulants Market: Company Share Analysis, 2020 (%)

Figure 12 Aptevo Biotherapeutics LLC: Key Financials

Figure 13 Aptevo Biotherapeutics LLC: Segmental Revenue

Figure 14 Aptevo Biotherapeutics LLC: Geographical Revenue

Figure 15 Baxalta US Inc.: Key Financials

Figure 16 Baxalta US Inc.: Segmental Revenue

Figure 17 Baxalta US Inc.: Geographical Revenue

Figure 18 Baxter Laboratories: Key Financials

Figure 19 Baxter Laboratories: Segmental Revenue

Figure 20 Baxter Laboratories: Geographical Revenue

Figure 21 Bayer AG: Key Financials

Figure 22 Bayer AG: Segmental Revenue

Figure 23 Bayer AG: Geographical Revenue

Figure 24 CSL Behring: Key Financials

Figure 25 CSL Behring: Segmental Revenue

Figure 26 CSL Behring: Geographical Revenue

Figure 27 GRIFOLS USA, LLC: Key Financials

Figure 28 GRIFOLS USA, LLC: Segmental Revenue

Figure 29 GRIFOLS USA, LLC: Geographical Revenue

Figure 30 Novo Nordisk A/S: Key Financials

Figure 31 Novo Nordisk A/S: Segmental Revenue

Figure 32 Novo Nordisk A/S: Geographical Revenue

Figure 33 Octapharma: Key Financials

Figure 34 Octapharma: Segmental Revenue

Figure 35 Octapharma: Geographical Revenue

Figure 36 Pfizer: Key Financials

Figure 37 Pfizer: Segmental Revenue

Figure 38 Pfizer: Geographical Revenue

Figure 39 Shire: Key Financials

Figure 40 Shire: Segmental Revenue

Figure 41 Shire: Geographical Revenue

Figure 42 SOBI: Key Financials

Figure 43 SOBI: Segmental Revenue

Figure 44 SOBI: Geographical Revenue

Blood Coagulants Market Scenario


Blood coagulants market is expected to grow significantly over the forecast period. It is estimated that the global market is expected to register a CAGR ~ 11.5% with an estimated market value of USD 720.7 million during the forecast period of 2018–2023.


The market is driven by factors such as increased bleeding disorders, the rise in the research activities and the increase in the healthcare project grants provided by public and private organizations, among others. Additionally, the growing awareness created by various non-profit organizations, as well as government campaigns helps to drive the growth of the market. For instance, the World Federation of Hemophilia (WFH) launched a Development Grant Program (DGP) in 2018 to encourage innovative ideas and projects to support the inherited bleeding disorders community globally. Moreover, key companies are actively involved in spreading awareness. For instance, in April 2018, CSL Behring shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to developing countries through the non-profit World Federation of Hemophilia (WFH) on account of World Hemophilia Day on April 17. The medicines were sent to countries like Vietnam, Cameroon, and others through the WFH’s Global Alliance for Progress (GAP) Program, which seeks to improve the diagnosis and treatment of bleeding disorders in developing countries.


On the other hand, the lack of awareness regarding blood clotting and its severity, the high cost of diagnostic tests in some economies, and the rising counterfeit drugs are restraining the growth of blood coagulants market. For instance, according to the statistics published by the National Hemophilia Foundation, annually 75% of hemophilic people worldwide receive inadequate treatment or have no access to treatment.


Moreover, major companies in the market are involved in strategic collaborations, and new product launches to brace their position in the market. For instance, in May 2016, CSL Behring announced the US FDA approval of AFSTYLA, a recombinant factor VIII Single Chain Therapy for Hemophilia A. Similarly, the drug received approval from European Commission (EC) in January 2017.


Segmentation


The blood coagulants market has been segmented into type and indication. The market, based on type, has been segmented into coagulation factor and others. The market, by coagulation factor, has been further segmented into recombinant coagulation factor and plasma-derived coagulation factor. The market, by indication, has been sub-segmented into hemophilia, surgery, and other bleeding disorders.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The blood coagulants market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European blood coagulants market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The blood coagulants market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The blood coagulants market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary Blood Coagulants Market Share (%), by Region, 2017


Source: World Health Organization (WHO), World Federation of Hemophilia (WFH)


Geographically, the Americas is expected to dominate the blood coagulants market due to the increasing per capita healthcare expenditure. The rise in product innovation and heavy adoption of new technology is anticipated to drive the growth of the market.


Europe showed a considerable amount of growth in the blood coagulants market. The market growth in this region is because of the presence of a well-established healthcare system and increase in marketing approvals and authorizations in the region. For instance, in June 2018, Octapharma announced that the European Medicines Agency (EMA) had approved an extension of marketing authorization for its product, Nuwiq, a human cell line-derived recombinant factor VIII (rFVIII) for the treatment in patients with hemophilia A.


Asia-Pacific is estimated to be the fastest growing region in the market due to the increasing number of welfare programs, coupled with the substantial generation of disposable income. Additionally, the increase in people suffering from bleeding disorders also propels the growth of the market in this region. According to the statistics published by Hemophilia Foundation Australia, Von Willebrand Disease (VWD), an inherited bleeding disorder affects approximately 200,000 people annually in Australia.


On the other hand, the Middle East & Africa has the least share of the market due to the poor access to treatment, and limited screening and diagnostic services in the region.


Blood Coagulants Market, by Type



  • Coagulation Factor


    • Recombinant Coagulation Factor

    • Plasma-Derived Coagulation Factor


  • Others


Blood Coagulants Market, by Indication



  • Hemophilia

  • Surgery

  • Other Bleeding Disorders


Blood Coagulants Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Middle East & Africa


    • Middle East

    • Africa



Blood Coagulants Market, by Key Players



  • Aptevo Biotherapeutics LLC

  • Baxalta US Inc.

  • Baxter Laboratories

  • Bayer AG

  • CSL Behring

  • GRIFOLS USA, LLC

  • Novo Nordisk A/S

  • Octapharma

  • Pfizer

  • Shire

  • SOBI


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities

  • Venture Capitalists



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The global blood coagulants market is expected to reach a valuation of USD 720.7 million by 2023.

The global blood coagulants market is expected to exhibit a strong 11.5% CAGR over the forecast period from 2018 to 2023.

The increasing prevalence of bleeding disorders is the major driver for the blood coagulants market.

The Americas is expected to be the dominant regional segment of the market over the forecast period.

Leading players in the blood coagulants market include SOBI, Bayer AG, Baxalta, Novo Nordisk, Pfizer, Shire, Grifols, and Baxter, among others.